Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1

Status

Completed 5

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 52Carcinoma, Renal Cell 25Liver Neoplasms 23Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 16Kidney Neoplasms 11Leukemia, Myeloid, Acute 9Melanoma 8Glioblastoma 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Pancreatic Neoplasms 5Gliosarcoma 5Urinary Bladder Neoplasms 4Recurrence 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Carcinoma 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leiomyosarcoma 3

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × Sorafenib × Clear all
NCT05068752 2026-03-30

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

HonorHealth Research Institute

Phase 2 Completed
10 enrolled 15 charts
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00634751 2019-11-26

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

University of Wisconsin, Madison

Phase 1/2 Completed
48 enrolled 13 charts
Gastrointestinal

Bile Duct Neoplasms, Pancreatic Neoplasms

NCT00696696 2016-06-30

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

NYU Langone Health

Phase 2 Completed
45 enrolled 8 charts
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT00114244 2015-01-14

Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00837876 2014-06-25

Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
37 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡